Hikma Pharmaceuticals (HKMPF) to Post Earnings on Thursday

Hikma Pharmaceuticals (OTCMKTS:HKMPF) will likely be posting its resultson Thursday, August 6th. Analysts expect Hikma Pharmaceuticals to announce earnings of $1.10 per share and revenue of $1.7030 billion for the quarter.

Hikma Pharmaceuticals Price Performance

HKMPF opened at $21.56 on Tuesday. The stock has a 50-day moving average price of $20.14 and a 200-day moving average price of $19.44. Hikma Pharmaceuticals has a 12-month low of $16.34 and a 12-month high of $26.38. The company has a current ratio of 1.82, a quick ratio of 1.06 and a debt-to-equity ratio of 0.57.

Wall Street Analyst Weigh In

Separately, Citigroup started coverage on Hikma Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.